Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Aeolus initiates studies of AEOL-10150 as a countermeasure to mustard gas exposure

Feb. 11, 2009

DOR BioPharma forms medical advisory board to advise on development of DOR-201

Jan. 28, 2009

Onconova successfully completes first dose cohort of phase I clinical trial of Ex-RAD

Jan. 27, 2009

Cleveland completes dosing of fourth cohort in safety study of Protectan CBLB-502 for ARS

Jan. 21, 2009

Nabi reaches agreement with FDA on SPA for a phase III clinical trial of NicVax

Jan. 5, 2009

Lundbeck initiates phase III clinical trials with nalmefene for alcohol dependence

Dec. 17, 2008

Alkermes initiates phase I ALKS-33 trial in healthy volunteers

Dec. 5, 2008

Alkermes regains U.S. commercialization rights to Vivitrol from Cephalon

Dec. 3, 2008

Aeolus initiates animal study of AEOL-10150 in damage to the lungs due to radiation

Nov. 25, 2008

Novel NMDA receptor modulator shows neuroprotection against ethanol withdrawal, consumption

Nov. 25, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 8, 2026.
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...